|
|
|
Upadacitinib (8)
|
Rinvoq®
|
AbbVie Deutschland GmbH & Co. KG
|
Musculoskeletal system diseases
|
Giant cell arteritis
|
13,100–15,900
|
20%
Hint for
minor additional benefit
|
|
|
|
Upadacitinib (7)
|
Rinvoq®
|
AbbVie Deutschland GmbH & Co. KG
|
Digestive system diseases
|
Morbus Crohn, pretreated
|
18,900–35,350
|
100%
additional benefit not proven
|
|
|
|
Upadacitinib (5)
|
Rinvoq®
|
AbbVie Deutschland GmbH & Co. KG
|
Digestive system diseases
|
Ulcerative colitis (UC), pre-treated
|
5,300–25,000
|
100%
additional benefit not proven
|
|
|
|
Upadacitinib (6)
|
Rinvoq®
|
AbbVie Deutschland GmbH & Co. KG
|
Musculoskeletal system diseases
|
Axial spondyloarthritis (AS), non-radiographic
|
19,500
|
100%
additional benefit not proven
|
|
|
|
Upadacitinib (4)
|
Rinvoq®
|
AbbVie Deutschland GmbH & Co. KG
|
Skin diseases
|
Atopic dermatitis (AD), ≥ 12 years
|
57,300–62,850
|
33%
Indication of
considerable additional benefit
|
|
|
|
Upadacitinib (2)
|
Rinvoq®
|
AbbVie Deutschland GmbH & Co. KG
|
Skin diseases
|
Psoriasis arthritis (PA)
|
29,100
|
69%
Hint for
considerable additional benefit
|
|
|
|
Upadacitinib (3)
|
Rinvoq®
|
AbbVie Deutschland GmbH & Co. KG
|
Musculoskeletal system diseases
|
Ankylosing spondylitis
|
7,800–16,800
|
100%
additional benefit not proven
|
|
|
|
Upadacitinib (1)
|
Rinvoq®
|
AbbVie Deutschland GmbH
|
Musculoskeletal system diseases
|
Rheumatoid arthritis (RA)
|
88,709–188,210
|
34%
Hint for
considerable additional benefit
|
|
|
start postponed
|
Upadacitinib (9)
|
Rinvoq®
|
AbbVie Deutschland GmbH & Co. KG
|
Skin diseases
|
Non-segmental vitiligo, aged 12 years or over
|
n.d.
|
active procedure
|
